CDK2 and cancer: Together, these data indicate that oncogenic activation of Cyclin E/CDK2 complex drives numerous forms of genomic instability in human cancers, ranging from whole chromosomal gains and/or losses to focal genomic deletions and/or amplifications, as well as chromosome rearrangements.